madame monsieur dans le cadre de l'apppel en cours du programme CIP, un défi traite de l'utilisation des technologies biophotoniques en diagnostic médical, voir ci-dessous : Pour favoriser les partenariats nécessaires pour répondre à cet appel, la Commission organise un ionfoday particulier avec possibilité de partage d'idée entre partenaires potentiels In the CIP 2013 Work Programme, the Photonics Unit of DG CONNECT has introduced an objective for pilot actions in the area of biophotonics. The call closes on 14 May 2013. On behalf of Thomas Skordas, Head of the Photonics Unit, we would like to draw your attention and ask you to spread the message that, following this call for proposals, an information day will be organised in Brussels on 15/04/2013. The venue is: Avenue de Beaulieu 25, ground floor, room Nr S1. The event will take place from 14:00 to 17:00. The agenda will include a presentation of the call by the EC; some information on the CIP rules for participation and the expected pilots; a Q&A session and some (optional) presentations by participants – the detailed agenda will be found at http://cordis.europa.eu/fp7/ict/photonics/calls-cip3-5_en.html. If you wish to attend this information day, please confirm your participation to by 08/04/2013, by replying to this address: CNECT-PHOTONICS@ec.europa.eu. People wishing to present key elements on biophotonics can do so with a maximum of 3 slides per presentation. Questions on specific topics can also already be sent beforehand if you wish them to be addressed during this information day. You may send your questions and presentations to: firstname.lastname@example.org. For more information on this call, including call text and FAQ: http://cordis.europa.eu/fp7/ict/photonics/calls-cip3-5_en.html. Objective 3.5: Biophotonics solutions for diagnosis, monitoring and treatment of diseases Funding instrument: Pilot B - It is intended to support 3-4 pilots for up to 10 M€ of total EU contribution Focus and outcomes The aim is to demonstrate in real application settings innovative biophotonics based solutions that offer a significant advantage over conventional approaches for the diagnosis, monitoring or treatment of disease. The solutions targeted should already have proven technical feasibility but they should not be commercially available yet. The pilots should serve to further develop and improve the solutions under a sufficient range of realistic conditions and disease profiles to be able to assess the applicability of the solution in reference to the gold standard where it exists. The outcome of pilots should be solutions which have been evaluated by professional end-users and which demonstrated significant advantages with respect to current approaches, with the ultimate goal being their introduction into the market place. Conditions and characteristics Examples of advantages with respect to currently approaches which could be offered by the targeted biophotonics based solutions are: – Earlier or faster diagnosis of disease, for example through the detection of biomarkers or other indicators of disease, allowing treatment of a disease to take place much sooner than is usually possible, and hence resulting in less invasive or more successful treatment. – More sensitive or more accurate monitoring of the progression of disease, allowing faster or pre-emptive intervention or allowing more accurate assessment of the effectiveness of a treatment. – Less invasive or more effective treatment of a disease than is currently possible. In addition: – The solutions involved should have proven their functionality with respect to the biological interaction mechanism in human patients. – The pilots should aim at evaluating and improving the performance of the solutions in routine care. Evaluation must be carried out in real-life conditions and should fit as far as possible in the clinical workflow, protocols and procedures as well as addressing the necessary regulatory and safety issues and providing the appropriate ethical and privacy safeguards. Other relevant issues such as standardization should be addressed as appropriate. – Clinical trials are not covered by these pilots and will normally take place after these pilots. – Pilots should have close involvement of professional end-users (for example physicians or clinicians) throughout the duration of the projects with the aim of ensuring acceptance and uptake. Usually these professional end-users will be those who have a particular expertise and experience with the disease targeted. Equipment manufacturers and/or other industrial players should be involved who are capable of and committed to the commercialisation of the biophotonics based solution. – Networking and coordination between the different pilots supported under this objective would be required in order to ensure maximum visibility and impact. Expected impact – Accelerated acceptance and wider deployment of innovative biophotonics based solutions, leading to more effective health care. – Increased competitiveness of the European medical equipment industry. – Improved health of citizens. Greater awareness of the potential of biophotonics based solutions in the health care sector.